Prescient Therapeutics Limited (PTX.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Rebecca Tunstall
|
Chief Operating Officer | -- | -- | -- |
|
Dr. Rosalind Wilson M.B.A., MBBS
|
Chief Medical Officer | -- | -- | -- |
Prescient Therapeutics Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
